Evidence map›Paper›PMID 36225598›Full record

ReviewFrontiers in bioengineering and biotechnology2022

Delivering the CRISPR/Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation.

Ruth A Foley, Ruby A Sims, Emily C Duggan, Jessica K Olmedo, Rachel Ma, Steven J Jonas

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. International journal of biological sciences · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Accelerating Diverse Cell-Based Therapies Through Scalable Design.Annual review of chemical and biomolecular engineering · 2024
    Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ruth A FoleyDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.
Ruby A SimsDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.
Emily C DugganDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.
Jessica K OlmedoDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.
Rachel MaDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.
Steven J JonasDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.
University of California, Los Angeles · USCalifornia NanoSystems Institute · US

Funding

Nanoscience-Inspired Acoustofluidic Assembly Lines for Gene and Cellular TherapiesDP5OD028181 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JONAS, STEVEN JOHN · 2019 to 2023
$1.9M
NIH HHS DP5 OD028181
6 · The paper itself

Abstract

Clustered Regularly Interspaced Short Palindromic Repeats associated protein 9 (CRISPR/Cas9) has transformed our ability to edit the human genome selectively. This technology has quickly become the most standardized and reproducible gene editing tool available. Catalyzing rapid advances in biomedical research and genetic engineering, the CRISPR/Cas9 system offers great potential to provide diagnostic and therapeutic options for the prevention and treatment of currently incurable single-gene and more complex human diseases. However, significant barriers to the clinical application of CRISPR/Cas9 remain. While

Indexed as

CRISPR/Cas9gene therapygenome editingintracellular deliverynano carriers

Identifiers

PMID36225598
PMCPMC9549251
OpenAlexW4297227056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.